Clinical Trial Update: Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 safety and tolerability study of INNO-406 for chronic myeloid leukemia and acute lymphoblastic leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia

Drugs mentioned

• INNO-406 (nilotinib)

Snippet

Sponsor: CytRx | Conditions: Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia | Phase 1 | Status: COMPLETED